Dulaglutide vs Palmitoyl Dipeptide-6
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
DulaglutideSkin & CosmeticAnti-Aging & Longevity
Palmitoyl Dipeptide-6- Summary
- Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
- Palmitoyl Dipeptide-6 is a synthetic dipeptide (lysine-threonine) with a palmitoyl fatty acid tail, designed to penetrate the skin barrier and stimulate the extracellular matrix components essential for skin firmness. It activates fibronectin and type IV collagen synthesis, improving skin density and firmness particularly in mature or sagging skin.
- Half-Life
- ~5 days
- Not applicable (topical)
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- 0.75 mg → 1.5 mg
- 0.005–0.05% in formulation
- Frequency
- Once weekly
- Once or twice daily
- Key Benefits
- FDA-approved for type 2 diabetes
- Once-weekly subcutaneous dosing via auto-injector pen
- Reduces HbA1c by approximately 1.1–1.6%
- Modest weight loss of 1.5–3 kg at approved doses
- Demonstrated cardiovascular risk reduction (REWIND trial)
- Established long-term safety profile
- Renal protective effects in CKD
- Increases skin firmness and density
- Stimulates fibronectin and collagen IV production
- Strengthens the dermal-epidermal junction
- Reduces skin sagging in mature skin
- Improves skin texture and smoothness
- Supports extracellular matrix integrity
- Side Effects
- Nausea (most common, typically transient)
- Diarrhea
- Vomiting
- Decreased appetite
- +3 more
- Generally well-tolerated
- Rare mild skin irritation in sensitive individuals
- No known systemic effects at cosmetic concentrations
- Stacks With
- —
- —